Kammy Moalemzadeh is the co-founder of the Luka Shai Foundation, where he has emerged as a driving force in the quest to understand and cure ATP6AP2-related diseases and other rare disorders. Since his son’s diagnosis, Kammy has immersed himself in the scientific landscape—learning complex biology, spearheading research strategies, designing experiments, and leading critical discussions with scientists, clinicians, and biotech leaders. His ability to rapidly absorb scientific knowledge and connect it to actionable research initiatives has positioned him as a key leader in the field of pediatric rare disease innovation.

Kammy leverages his strategic and analytical expertise to guide the foundation’s research funding, partnership development, and growth initiatives. He is known for his relentless problem-solving mindset, often crafting innovative approaches to scientific challenges and driving forward experimental strategies that push the boundaries of current research.

Professionally, Kammy is the Founder and Managing Partner of Arcadia Investment Partners, an SEC-registered investment advisor specializing in private equity, real estate, and special situations investments. Arcadia manages capital on behalf of its own balance sheet, alongside limited partners including ultra-high-net-worth families and institutional investors.

Before founding Arcadia, Kammy served as a Managing Director at Mentmore Holdings and was part of the Merchant Banking Division at Donaldson, Lufkin & Jenrette (DLJ). He is a graduate of The Wharton School at the University of Pennsylvania, where he honed his expertise in finance and investment strategy.

Through his work with the foundation, Kammy brings together scientific insight, strategic thinking, and an unyielding commitment to finding cures—making him a leading figure in the effort to advance research and change outcomes for children affected by rare diseases.